Skip to Main Content

1,625

Views

1

CrossRef citations to date

0

Altmetric

Original Research Article

Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials

Lin Fana Health Economics and Decision Science, Merck & Co., Inc, Rahway, NJ, USAView further author information

,

Yuanyuan Zhangb Health Economics and Evidence Generation, Wickenstones Ltd, Milton Park, Oxfordshire, UKCorrespondence[email protected]
View further author information

,

Peter Maguireb Health Economics and Evidence Generation, Wickenstones Ltd, Milton Park, Oxfordshire, UKView further author information

,

Dominic Mustona Health Economics and Decision Science, Merck & Co., Inc, Rahway, NJ, USAView further author information

,

Matthew Monbergc Center for Observational and Real-World Evidence, Merck & Co., Inc, Rahway, NJ, USAView further author information

,

Jagadeswara Rao Earlac Center for Observational and Real-World Evidence, Merck & Co., Inc, Rahway, NJ, USAView further author information

,

Adela Mihaid Global Health Economics and Payer Evidence, AstraZeneca PLC, Cambridge, UKView further author information

&

Poonam Gulatie Global Regulatory Affairs, AstraZeneca PLC, Cambridge, UKView further author information